Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9VKXC)

• Drug Name: dipropyl-5-CT Drug Info
• Synonyms: DP-5-CT; DP5CT; N,N-dipropylcarboxamidotryptamine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 156314
  ChEBI ID: CHEBI:92566
  CAS Number: CAS 74885-25-9
  TTD Drug ID: DM9VKXC

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[6]
Eletriptan	DMW649X	Migraine	8A80	Approved	[7]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[7]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[7]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[7]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[8]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[7]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[9]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[10]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[11]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[12]
Eletriptan	DMW649X	Migraine	8A80	Approved	[7]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[7]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[7]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[13]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[14]
Almogran	DM7I64Z	Migraine	8A80	Approved	[15]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[16]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[17]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[10]

Drug(s) Targeting 5-HT 1F receptor (HTR1F)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[18]
Lasmiditan	DMXLVDT	Migraine	8A80	Approved	[19]
LY-334370	DM43O9N	Migraine	8A80	Phase 2	[20]
5-CT	DM260KD	Discovery agent	N.A.	Investigative	[18]
TFMPP	DMAC8TP	Discovery agent	N.A.	Investigative	[3]
1-naphthylpiperazine	DM6BIWK	Discovery agent	N.A.	Investigative	[18]
BRL-15572	DMM61Y2	Discovery agent	N.A.	Investigative	[21]
2-methyl-5-HT	DM1S5CB	N. A.	N. A.	Investigative	[3]
alpha-methyl-5-HT	DMCAYXF	Discovery agent	N.A.	Investigative	[3]
WAY-466	DMMOH51	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[17]
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[23]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[24]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[25]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[26]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[26]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[27]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[27]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[28]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[29]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[30]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[31]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[32]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[33]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[34]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[35]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[36]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[37]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[38]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[39]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Agonist	[2]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Agonist	[2]
5-HT 1F receptor (HTR1F)	TT0MI3F	5HT1F_HUMAN	Agonist	[3]
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Agonist	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 122).
• [2] Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
• [3] Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
• [4] Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol. 1997 Sep;122(1):126-32.
• [5] Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. Chem Res Toxicol. 1998 Dec;11(12):1447-52.
• [6] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [9] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [10] Company report (NeurAxon)
• [11] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [12] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [13] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [14] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [15] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [16] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [20] Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4.
• [21] SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
• [22] Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
• [23] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [24] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [25] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [26] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [27] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [28] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [29] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [30] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [31] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [32] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [33] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [34] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [35] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [36] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [37] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [38] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [39] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.